Patents by Inventor Bruce Yacyshyn

Bruce Yacyshyn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
    Patent number: 11199534
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: December 14, 2021
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn
  • Industrial operation having a monitoring system and method
    Patent number: 10433708
    Abstract: An industrial operation having a system for remotely investigating and monitoring chemical reactions and structural and environmental conditions within the components of the industrial operation. The system includes a capsule having cameras within the capsule that operates to acquire data which is communicated to a monitor and relates to structural, environmental, chemical and/or fluid conditions within the components of the industrial operation.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 8, 2019
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn
  • PROCESS AND SYSTEM FOR PREDICTING RESPONDERS AND NON-RESPONDERS TO MESALAMINE TREATMENT OF ULCERATIVE COLITIS
    Publication number: 20190242872
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.
    Type: Application
    Filed: March 29, 2019
    Publication date: August 8, 2019
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn
  • Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
    Patent number: 10295527
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: May 21, 2019
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn
  • PROCESS AND SYSTEM FOR PREDICTING RESPONDERS AND NON-RESPONDERS TO MESALAMINE TREATMENT OF ULCERATIVE COLITIS
    Publication number: 20170261492
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.
    Type: Application
    Filed: March 14, 2016
    Publication date: September 14, 2017
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn